US5217996A
(en)
*
|
1992-01-22 |
1993-06-08 |
Ciba-Geigy Corporation |
Biaryl substituted 4-amino-butyric acid amides
|
HRP950558A2
(en)
*
|
1994-11-15 |
1997-12-31 |
Scott M. Wilhelm |
Substituted 4-biarylbutric or biarylpentanoic acids and derivatives as matrix metalloprotease inhibitors
|
NZ300942A
(en)
*
|
1995-02-22 |
1998-12-23 |
Novartis Ag |
1-aryl-2-acylamino-ethane derivatives as neurokinin 1 antagonists
|
MY132550A
(en)
|
1996-08-22 |
2007-10-31 |
Novartis Ag |
Acylaminoalkenylene-amide derivatives as nk1 and nk2 antogonists
|
IL144285A0
(en)
*
|
1999-03-29 |
2002-05-23 |
Bristol Myers Squibb Co |
Pharmaceutical compositions containing a vasopeptidase inhibitor
|
EP1467728B1
(en)
*
|
2002-01-17 |
2007-08-22 |
Novartis AG |
Pharmaceutical compositions comprising valsartan and nep inhibitors
|
US7468390B2
(en)
*
|
2002-01-17 |
2008-12-23 |
Novartis Ag |
Methods of treatment and pharmaceutical composition
|
GB0203061D0
(en)
*
|
2002-02-08 |
2002-03-27 |
Novartis Ag |
Organic compounds
|
ATE550656T1
(de)
*
|
2003-08-20 |
2012-04-15 |
Alere San Diego Inc |
Verfahren und zusammensetzungen zur messung biologisch aktiver natriuretischer peptide und zur verbesserung ihres therapeutischen potentials
|
US7781478B2
(en)
*
|
2004-07-14 |
2010-08-24 |
Ptc Therapeutics, Inc. |
Methods for treating hepatitis C
|
US7868037B2
(en)
*
|
2004-07-14 |
2011-01-11 |
Ptc Therapeutics, Inc. |
Methods for treating hepatitis C
|
EA200700243A1
(ru)
*
|
2004-07-14 |
2007-08-31 |
ПиТиСи ТЕРАПЬЮТИКС, ИНК. |
Способы лечения гепатита с
|
US7772271B2
(en)
*
|
2004-07-14 |
2010-08-10 |
Ptc Therapeutics, Inc. |
Methods for treating hepatitis C
|
WO2006019832A1
(en)
|
2004-07-22 |
2006-02-23 |
Ptc Therapeutics, Inc. |
Thienopyridines for treating hepatitis c
|
MY146830A
(en)
*
|
2005-02-11 |
2012-09-28 |
Novartis Ag |
Combination of organic compounds
|
WO2007045663A2
(en)
*
|
2005-10-19 |
2007-04-26 |
Novartis Ag |
Combination of an ati receptor antagonist and a np inhibitor fro treating ia hypertension and heartfailure
|
RU2459809C2
(ru)
*
|
2005-11-09 |
2012-08-27 |
Новартис Аг |
Фармацевтические комбинации антагониста рецептора ангиотензина и ингибитора nep
|
AR057882A1
(es)
*
|
2005-11-09 |
2007-12-26 |
Novartis Ag |
Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
|
EP1903027A1
(en)
*
|
2006-09-13 |
2008-03-26 |
Novartis AG |
Process for preparing biaryl substituted 4-amino-butyric acid or derivatives thereof and their use in the production of NEP inhibitors
|
JP5715339B2
(ja)
*
|
2007-01-12 |
2015-05-07 |
ノバルティス アーゲー |
5−ビフェニル−4−アミノ−2−メチルペンタン酸の製造方法
|
TW200838501A
(en)
*
|
2007-02-02 |
2008-10-01 |
Theravance Inc |
Dual-acting antihypertensive agents
|
TWI448284B
(zh)
*
|
2007-04-24 |
2014-08-11 |
Theravance Inc |
雙效抗高血壓劑
|
TWI406850B
(zh)
|
2007-06-05 |
2013-09-01 |
Theravance Inc |
雙效苯并咪唑抗高血壓劑
|
WO2009035543A1
(en)
|
2007-09-07 |
2009-03-19 |
Theravance, Inc. |
Dual-acting antihypertensive agents
|
MX2010003668A
(es)
*
|
2007-10-05 |
2010-07-02 |
S Bio Pte Ltd |
Derivados de purina sustituidas con primidina.
|
WO2009076288A1
(en)
|
2007-12-11 |
2009-06-18 |
Theravance, Inc. |
Dual-acting benzoimidazole derivative and their use as antihypertensive agents
|
AU2012202949B2
(en)
*
|
2008-01-17 |
2015-01-22 |
Novartis Ag |
Process and intermediates for the preparation of 5-biphenyl-4-yl-2-methylpentanoic acid derivatives
|
AR070176A1
(es)
|
2008-01-17 |
2010-03-17 |
Novartis Ag |
Procesos de sintesis de inhibidores de nep, compuestos intermediarios y uso de los mismos en la sintesis
|
US7989484B2
(en)
|
2008-04-29 |
2011-08-02 |
Theravance, Inc. |
Dual-acting antihypertensive agents
|
CN101607875B
(zh)
*
|
2008-06-17 |
2012-07-25 |
中国石油化学工业开发股份有限公司 |
制造环烷酮的方法
|
US7863309B2
(en)
|
2008-07-24 |
2011-01-04 |
Theravance, Inc. |
Dual-acting antihypertensive agents
|
CN101774941A
(zh)
*
|
2009-01-13 |
2010-07-14 |
浙江九洲药业股份有限公司 |
2-酰基氨基-3-联苯基丙酸的制备及拆分方法
|
WO2010132127A1
(en)
|
2009-05-13 |
2010-11-18 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
KR20120041702A
(ko)
*
|
2009-05-28 |
2012-05-02 |
노파르티스 아게 |
네프릴리신 억제제로서의 치환된 아미노부티르산 유도체
|
CN103896796B
(zh)
*
|
2009-05-28 |
2016-04-27 |
诺华股份有限公司 |
作为脑啡肽酶抑制剂的取代的氨基丙酸衍生物
|
JP5833000B2
(ja)
|
2009-07-07 |
2015-12-16 |
セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー |
二重に作用するピラゾール抗高血圧症薬
|
US8372984B2
(en)
|
2009-07-22 |
2013-02-12 |
Theravance, Inc. |
Dual-acting oxazole antihypertensive agents
|
JO2967B1
(en)
*
|
2009-11-20 |
2016-03-15 |
نوفارتس ايه جي |
Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
|
JP2013517295A
(ja)
|
2010-01-19 |
2013-05-16 |
セラヴァンス, インコーポレーテッド |
二重に作用するチオフェン、ピロール、チアゾールおよびフラン抗高血圧症薬
|
JP5600183B2
(ja)
*
|
2010-01-22 |
2014-10-01 |
ノバルティス アーゲー |
中性エンドペプチダーゼ阻害剤の中間体およびその調製方法
|
WO2012025502A1
(en)
*
|
2010-08-23 |
2012-03-01 |
Novartis Ag |
New process for the preparation of intermediates useful for the manufacture nep inhibitors
|
RU2588572C2
(ru)
*
|
2010-08-23 |
2016-07-10 |
Новартис Аг |
Способ получения промежуточных соединений для получения ингибиторов nep
|
MA34483B1
(fr)
|
2010-08-24 |
2013-08-01 |
Novartis Ag |
Traitement de l'hypertension et/ou prévention ou traitement de l'insuffisance cardiaque l'insuffisance cardiaque chez un mammifère recevant une therapie anticoagulante
|
US8993631B2
(en)
*
|
2010-11-16 |
2015-03-31 |
Novartis Ag |
Method of treating contrast-induced nephropathy
|
US8673974B2
(en)
*
|
2010-11-16 |
2014-03-18 |
Novartis Ag |
Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
|
CA2819153A1
(en)
|
2010-12-15 |
2012-06-21 |
Theravance, Inc. |
Neprilysin inhibitors
|
NZ610983A
(en)
|
2010-12-15 |
2014-10-31 |
Theravance Biopharma R & D Ip Llc |
Neprilysin inhibitors
|
ES2564275T3
(es)
|
2011-02-17 |
2016-03-21 |
Theravance Biopharma R&D Ip, Llc |
Derivados aminobutíricos sustituidos como inhibidores de neprilisina
|
CA2825737C
(en)
|
2011-02-17 |
2018-11-13 |
Theravance, Inc. |
Substituted aminobutyric derivatives as neprilysin inhibitors
|
US8513244B2
(en)
|
2011-05-31 |
2013-08-20 |
Theravance, Inc. |
Neprilysin inhibitors
|
CA2835220A1
(en)
|
2011-05-31 |
2012-12-06 |
Theravance, Inc. |
Neprilysin inhibitors
|
US8686184B2
(en)
|
2011-05-31 |
2014-04-01 |
Theravance, Inc. |
Neprilysin inhibitors
|
TWI560172B
(en)
|
2011-11-02 |
2016-12-01 |
Theravance Biopharma R&D Ip Llc |
Neprilysin inhibitors
|
AR089955A1
(es)
*
|
2012-02-15 |
2014-10-01 |
Theravance Inc |
Proceso para preparar compuestos de acido 4-amino-5-bifenil-4-il-2-hidroximetil-2-metil-pentanoico
|
EP2855464B1
(en)
|
2012-05-31 |
2016-10-26 |
Theravance Biopharma R&D IP, LLC |
Nitric oxide donor neprilysin inhibitors
|
WO2013184898A1
(en)
|
2012-06-08 |
2013-12-12 |
Theravance, Inc. |
Neprilysin inhibitors
|
MX356260B
(es)
|
2012-06-08 |
2018-05-21 |
Theravance Biopharma R&D Ip Llc |
Inhibidores de la neprilisina.
|
CA2879697C
(en)
|
2012-08-08 |
2020-07-07 |
Theravance Biopharma R&D Ip, Llc |
Neprilysin inhibitors
|
WO2014029848A1
(en)
|
2012-08-24 |
2014-02-27 |
Novartis Ag |
Nep inhibitors for treating diseases characterized by atrial enlargement or remodeling
|
EA026989B1
(ru)
|
2013-02-14 |
2017-06-30 |
Новартис Аг |
Производные замещенной бисфенилбутановой кислоты в качестве ингибиторов nep с улучшенной in vivo эффективностью
|
PL2956464T3
(pl)
|
2013-02-14 |
2018-08-31 |
Novartis Ag |
Podstawione pochodne bisfenylowe kwasu butanowofosfonowego jako inhibitory nep (neutralnej endopeptydazy)
|
EP2956141A4
(en)
|
2013-02-17 |
2016-10-26 |
Intra Cellular Therapies Inc |
NEW USES
|
ME02937B
(me)
|
2013-03-05 |
2018-04-20 |
Theravance Biopharma R&D Ip Llc |
Inhibitori neprilizina
|
CN104230865B
(zh)
*
|
2013-06-13 |
2018-01-09 |
上海翰森生物医药科技有限公司 |
联芳基取代的4‑氨基丁酸衍生物及其制备方法和用途
|
EP3038654B1
(en)
|
2013-08-26 |
2019-10-30 |
Novartis AG |
New use
|
US20160206597A1
(en)
|
2013-08-26 |
2016-07-21 |
Toni Lynne Bransford |
New Use
|
MX2016009759A
(es)
|
2014-01-30 |
2016-11-17 |
Theravance Biopharma R&D Ip Llc |
Inhibidores de neprilisina.
|
MX2016009760A
(es)
|
2014-01-30 |
2016-11-08 |
Theravance Biopharma R&D Ip Llc |
Inhibidores de neprilisina.
|
WO2015154673A1
(en)
*
|
2014-04-10 |
2015-10-15 |
Zhaoyin Wang |
Novel prodrugs and combinations for treatment of hypertension and cardiovascular diseases
|
US10131671B2
(en)
|
2014-08-07 |
2018-11-20 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
CN105367438A
(zh)
*
|
2014-08-27 |
2016-03-02 |
上海翰森生物医药科技有限公司 |
AHU-377α-苯乙胺盐多晶型及其制备方法和应用
|
CN106458857A
(zh)
*
|
2014-08-27 |
2017-02-22 |
上海翰森生物医药科技有限公司 |
AHU‑377结晶型游离酸、半钙盐、α﹣苯乙胺盐及其制备方法和应用
|
CN105622452A
(zh)
*
|
2014-08-27 |
2016-06-01 |
上海翰森生物医药科技有限公司 |
Ahu-377结晶型游离酸及其制备方法和应用
|
CN105461587A
(zh)
*
|
2014-08-27 |
2016-04-06 |
上海翰森生物医药科技有限公司 |
Ahu-377半钙盐晶型及其制备方法和应用
|
WO2016037098A1
(en)
|
2014-09-04 |
2016-03-10 |
Concert Pharmaceuticals, Inc. |
Deuterated sacubitril
|
DK3218351T3
(da)
|
2014-11-14 |
2019-09-16 |
Zentiva Ks |
Fremgangsmåde til fremstilling, isolering og oprensning af farmaceutisk anvendelige former af ahu-377
|
CN105693543B
(zh)
*
|
2014-12-15 |
2018-08-10 |
四川海思科制药有限公司 |
沙库比曲类衍生物、其药物组合物、制备方法及用途
|
CN104557600B
(zh)
*
|
2015-01-26 |
2016-05-04 |
苏州明锐医药科技有限公司 |
沙库比曲的制备方法
|
ES2923002T3
(es)
|
2015-02-11 |
2022-09-22 |
Theravance Biopharma R&D Ip Llc |
Acido (2S,4R)-5-(5'-cloro-2'-fluorobifenil-4-il)-4-(etoxioxailamino)-2-hidroximetil-2-metilpentanoico como inhibidor de la neprilisina
|
TW201632493A
(zh)
|
2015-02-13 |
2016-09-16 |
諾華公司 |
新穎方法
|
WO2016133803A1
(en)
|
2015-02-19 |
2016-08-25 |
Theravance Biopharma R&D Ip, Llc |
(2r,4r)-5-(5'-chloro-2'-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid
|
WO2016135751A1
(en)
|
2015-02-25 |
2016-09-01 |
Mylan Laboratories Limited |
Novel process for the preparation of sacubitril and its intermediates
|
CN110801452B
(zh)
*
|
2015-03-12 |
2023-01-13 |
深圳信立泰药业股份有限公司 |
一种含有阿利沙坦酯水解产物或其水解产物盐的药物组合物及其用途
|
EP3272734A4
(en)
*
|
2015-03-20 |
2018-11-21 |
Crystal Pharmatech Co., Ltd. |
Ahu377 crystal form, preparation method and use thereof
|
ES2945866T3
(es)
|
2015-05-11 |
2023-07-10 |
Novartis Ag |
Pauta posológica de sacubitrilo-valsartán para el tratamiento de la insuficiencia cardíaca
|
EP3302460A1
(en)
|
2015-05-29 |
2018-04-11 |
Novartis AG |
Sacubitril and valsartan for treating metabolic disease
|
CN104860894B
(zh)
*
|
2015-06-10 |
2017-05-17 |
北京博全健医药科技有限公司 |
一种抗心衰药lcz696的制备方法
|
EP3307720A1
(en)
|
2015-06-12 |
2018-04-18 |
Teva Pharmaceuticals International GmbH |
Solid state forms of trisodium valsartan: sacubitril
|
WO2016203500A2
(en)
|
2015-06-19 |
2016-12-22 |
Actavis Group Ptc Ehf. |
Preparation of sacubitril or salt thereof and novel intermediates in the preparation of sacubitril
|
HUE052222T2
(hu)
*
|
2015-07-02 |
2021-04-28 |
Novartis Ag |
Sacubitril kalciumsók
|
WO2017006254A1
(en)
|
2015-07-08 |
2017-01-12 |
Novartis Ag |
Drug combination comprising an angiotensin ii receptor antagonist, a neutral endopeptidase inhibitor and a mineralcorticoid receptor antagonist
|
WO2017009784A1
(en)
|
2015-07-14 |
2017-01-19 |
Cadila Healthcare Limited |
Solid state forms of trisodium salt of valsartan/sacubitril complex and sacubitril
|
WO2017012600A1
(en)
|
2015-07-20 |
2017-01-26 |
Zentiva, K.S. |
A pharmaceutical composition containing valsartan and sacubitril and methods for preparation and stabilization thereof
|
HUE052337T2
(hu)
|
2015-07-23 |
2021-04-28 |
Bayer Pharma AG |
Oldható guanilát-cikláz stimulátorai/aktivátorai a neutrális endopeptidáz egy inhibitorával (NEP-inhibitor) és/vagy egy angiotenzin All-antagonistával kombinációban és ezek alkalmazása
|
WO2017029261A1
(de)
*
|
2015-08-19 |
2017-02-23 |
Bayer Pharma Aktiengesellschaft |
Kombinationspräparat umfassend finerenone und einen nep-inhibitor (sacubitril)
|
WO2017033128A1
(en)
|
2015-08-25 |
2017-03-02 |
Novartis Ag |
Biphenyl-substitued 4-amino-butyric acid derivatives and their use in the synthesis of nep inhibitors
|
JP6598985B2
(ja)
|
2015-08-28 |
2019-10-30 |
ノバルティス アーゲー |
新規の使用
|
WO2017051326A1
(en)
|
2015-09-23 |
2017-03-30 |
Novartis Ag |
New processes and intermediates useful in synthesis of nep inhibitors
|
WO2017072636A1
(en)
|
2015-10-29 |
2017-05-04 |
Cadila Healthcare Limited |
Pharmaceutical synergistic combination
|
EP3386955B1
(en)
|
2015-12-10 |
2020-08-05 |
Novartis AG |
Intermediates for the preparation of sacubitril and their preparation
|
BR112018011788A2
(pt)
*
|
2015-12-11 |
2018-12-04 |
Zentiva Ks |
formas sólidas de éster etílico de ácido (2r,4s)-5-(bifenil-4-il)-4-[(3-carboxipropionil)amino]-2-metil-pentanoico, seus sais e um método de preparação
|
CN106977417A
(zh)
*
|
2016-01-15 |
2017-07-25 |
常州方楠医药技术有限公司 |
一种沙库比曲钠盐的晶型及其制备方法
|
WO2017134600A1
(en)
|
2016-02-03 |
2017-08-10 |
Novartis Ag |
New use of a combination of sacubitril and valsartan
|
KR20220035991A
(ko)
|
2016-03-08 |
2022-03-22 |
세라밴스 바이오파마 알앤디 아이피, 엘엘씨 |
(2s,4r)-5-(5'-클로로-2'-플루오로-[1,1'-비페닐]-4-일)-2-(에톡시메틸)-4-(3-히드록시이속사졸-5-카르복사미도)-2-메틸펜탄산 결정 및 그 용도
|
EP3436083A4
(en)
|
2016-03-28 |
2019-11-27 |
Intra-Cellular Therapies, Inc. |
NEW COMPOSITIONS AND METHODS
|
CN105753733B
(zh)
*
|
2016-04-15 |
2019-06-18 |
苏州晶云药物科技股份有限公司 |
Ahu377的晶型及其制备方法与用途
|
CN105820064A
(zh)
*
|
2016-04-18 |
2016-08-03 |
浙江天宇药业股份有限公司 |
一种联苯基丙氨醇衍生物的合成方法及中间体
|
WO2017191620A1
(en)
*
|
2016-05-06 |
2017-11-09 |
Sun Pharmaceutical Industries Limited |
A crystalline form of a salt of sacubitril and a process of its preparation
|
US20190256454A1
(en)
|
2016-07-05 |
2019-08-22 |
Novartis Ag |
New process for early sacubitril intermediates
|
CN107602399B
(zh)
*
|
2016-07-11 |
2020-09-25 |
江西东邦药业有限公司 |
一种脑啡肽酶抑制剂中间体的制备方法
|
CN109563019A
(zh)
*
|
2016-08-17 |
2019-04-02 |
诺华股份有限公司 |
Nep抑制剂合成的新方法和中间体
|
CN106318988B
(zh)
*
|
2016-08-23 |
2020-11-03 |
迪嘉药业集团有限公司 |
一种lcz696关键中间体的制备方法
|
CN109661386A
(zh)
*
|
2016-09-07 |
2019-04-19 |
诺瑞特国际药业股份有限公司 |
沙库比曲钠盐新晶型
|
CN106478437A
(zh)
*
|
2016-09-27 |
2017-03-08 |
南通常佑药业科技有限公司 |
一种γ‑氨基戊酸酯衍生物的制备方法
|
CN106496055A
(zh)
*
|
2016-10-09 |
2017-03-15 |
杭州科巢生物科技有限公司 |
一种抗心衰新药的关键组分沙库比曲的新合成方法
|
EP3522886A4
(en)
|
2016-10-10 |
2020-02-19 |
Laurus Labs Limited |
STABLE AMORPHE FORM OF THE SACUBITRIL VALSARTAN TRINATRIUM COMPLEX AND METHOD FOR THE PRODUCTION THEREOF
|
JP7022747B2
(ja)
|
2016-10-28 |
2022-02-18 |
バイオコン・リミテッド |
アモルファスサクビトリルバルサルタン三ナトリウムおよびその調製のためのプロセス
|
CN110088079A
(zh)
|
2016-12-23 |
2019-08-02 |
诺华股份有限公司 |
用于早期沙卡布曲中间体的新方法
|
CN106831473B
(zh)
*
|
2017-02-22 |
2019-07-16 |
江西瑞雅药业有限公司 |
3-酰胺基-4-(2’-烷氧基-4-联苯基)丁酸衍生物及其制备方法、药物组合物
|
WO2018153895A1
(de)
|
2017-02-22 |
2018-08-30 |
Bayer Pharma Aktiengesellschaft |
Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit einem inhibitor der neutralen endopeptidase und/oder einem angiotensin ii rezeptor-antagonisten
|
WO2018178295A1
(en)
|
2017-03-31 |
2018-10-04 |
Alfred E. Tiefenbacher (Gmbh & Co. Kg) |
Stable hot-melt extrudate containing valsartan and sacubitril
|
PL3658122T3
(pl)
|
2017-07-28 |
2021-10-18 |
Synthon B.V. |
Kompozycja farmaceutyczna zawierająca sakubitryl i walsartan
|
WO2019073062A1
(en)
|
2017-10-13 |
2019-04-18 |
Alfred E. Tiefenbacher (Gmbh & Co. Kg) |
TABLET CONTAINING VALSARTAN AND SACUBITRIL
|
CN108530371B
(zh)
*
|
2017-12-27 |
2020-09-01 |
浙江天宇药业股份有限公司 |
一种沙库比曲钠盐、沙库比曲游离酸与乙酸的共晶物、其晶型、晶型的制备方法及用途
|
JP7401442B2
(ja)
|
2018-01-31 |
2023-12-19 |
イントラ-セルラー・セラピーズ・インコーポレイテッド |
新規使用
|
UY38072A
(es)
*
|
2018-02-07 |
2019-10-01 |
Novartis Ag |
Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
|
GB201810326D0
(en)
*
|
2018-06-22 |
2018-08-08 |
Johnson Matthey Plc |
Crystalline form of sacubitril, its preparation and use
|
US20210177803A1
(en)
|
2018-08-23 |
2021-06-17 |
Novartis Ag |
New pharmaceutical use for the treatment of heart failure
|
WO2020039394A1
(en)
|
2018-08-24 |
2020-02-27 |
Novartis Ag |
New drug combinations
|
CN109503404A
(zh)
*
|
2018-12-28 |
2019-03-22 |
凯瑞斯德生化(苏州)有限公司 |
一种lcz-696关键中间体的制备方法
|
CN110128298B
(zh)
*
|
2019-06-13 |
2021-08-03 |
南京一心和医药科技有限公司 |
一种沙库巴曲中间体的合成方法
|
CN113135836A
(zh)
*
|
2020-01-20 |
2021-07-20 |
鲁南制药集团股份有限公司 |
一种沙库巴曲钙盐的制备方法
|
CN111253425B
(zh)
*
|
2020-02-21 |
2022-04-29 |
常州南京大学高新技术研究院 |
一种1,3-双[2-(3,4-环氧环己基)乙基]四甲基二硅氧烷的合成方法
|
JP7064527B2
(ja)
*
|
2020-05-01 |
2022-05-10 |
ノバルティス アーゲー |
サクビトリルカルシウム塩
|
KR20220012821A
(ko)
|
2020-07-23 |
2022-02-04 |
주식회사 종근당 |
이중 작용 복합 화합물의 결정형 및 이의 제조방법
|
CN112661671B
(zh)
*
|
2020-12-22 |
2022-04-22 |
江苏阿尔法药业股份有限公司 |
一种沙库巴曲中间体的制备方法
|
WO2022224274A1
(en)
|
2021-04-20 |
2022-10-27 |
Mylan Laboratories Limited |
Polymorphic forms of sacubitril-telmisartan (1:1)
|